Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 10/20 | 0.51 |
| ▸ | KDR | P35968 | 8/20 | 0.51 |
| ▸ | LRRK2 | Q5S007 | 7/20 | 0.51 |
| ▸ | LCK | P06239 | 7/20 | 0.51 |
| ▸ | PDGFRA | P16234 | 5/20 | 0.51 |
| ▸ | ALK | Q9UM73 | 5/20 | 0.51 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.43 |
| ▸ | TLK2 | Q86UE8 | 3/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.41 |
| ▸ | CDK1 | P06493 | 2/20 | 0.41 |
| ▸ | CDK2 | P24941 | 2/20 | 0.41 |
| ▸ | GSK3A | P49840 | 2/20 | 0.41 |
| ▸ | GSK3B | P49841 | 2/20 | 0.41 |
| ▸ | CDK7 | P50613 | 2/20 | 0.41 |
| ▸ | CDK9 | P50750 | 2/20 | 0.41 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6532496 | 1.00 | RET (0.51) | RETKDRLRRK2LCKPDGFRA | |
| SCHEMBL10099845 | 1.00 | RET (0.51) | RETKDRLRRK2LCKPDGFRA | |
| SCHEMBL3791287 | 0.89 | KIT (0.49) | RETGSK3BAURKBPLK4PIM1 | |
| SCHEMBL12795194 | 0.89 | KIT (0.49) | RETGSK3BAURKBPLK4PIM1 | |
| SCHEMBL3791289 | 0.89 | KIT (0.49) | RETGSK3BAURKBPLK4PIM1 | |
| SCHEMBL6519117 | 0.86 | LRRK2 (0.51) | RETKDRLRRK2LCKTLK2 | |
| SCHEMBL6519115 | 0.86 | LRRK2 (0.51) | RETKDRLRRK2LCKTLK2 | |
| SCHEMBL6519110 | 0.86 | LRRK2 (0.51) | RETKDRLRRK2LCKTLK2 | |
| SCHEMBL2548124 | 0.83 | PLK4 (0.52) | RETKDRLRRK2LCKPDGFRA | |
| SCHEMBL2548126 | 0.83 | PLK4 (0.52) | RETKDRLRRK2LCKPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8765748-B2 | Indazolyl, benzimidazolyl, benzotriazolyl substituted indolinone derivatives as kinase inhibitors useful in the treatment of cancer | UNIVERSITY HEALTH NETWORK (CA) | 2014-07-01 | — | — | US | disclosed |
| US-20110065702-A1 | INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLINONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | UNIVERSITY HEALTH NETWORK | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065702-A1 | INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLINONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | TNNI3K, ABL1, TK1 | RET 234/4885KDR 679/4885LRRK2 254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.